http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Difficulties faced by children with disabilities and their families in the event of a disaster
KOBAYASHI Tomoko,ISHIKAWA Rei,OISHI Hirofumi 아시아장애사회학회 2011 아시아장애사회학연구 Vol.11 No.-
It is necessary to shed light on difficulties faced by parents in the event of a disaster We studied that was to shed light on the difficulties faced by the parents of disabled children in the event of a disaster. The results showed that “home" was seleded by the highest number of respondents as shelter life place, followed by "car". On the other hand, number of users of "regional evacuation center" was 1/3 rd of that of “ home 씨 and around 2/3 rd of that of “car. Establis hment of such evacuation centers with much beUer support facilities compared to ordinary evacuation centers to ensure that disabled children , disabled people and their family need not live at home or in car feeling unsecured and unsafe, is extremely beneficial ‘
TP53 variants in p53 signatures and the clonality of STICs in RRSO samples
Tomoko Akahane,Kenta Masuda,Akira Hirasawa,Yusuke Kobayashi,Arisa Ueki,Miho Kawaida,Kumiko Misu,Kohei Nakamura,Shimpei Nagai,Tatsuyuki Chiyoda,Wataru Yamagami,Shigenori Hayashi,Fumio Kataoka,Kouji Ban 대한부인종양학회 2022 Journal of Gynecologic Oncology Vol.33 No.4
Objective: Precursor lesions may be identified in fallopian tube tissue after risk-reducing salpingo-oophorectomy (RRSO) in patients with pathogenic variants of . Serous tubal intraepithelial carcinoma (STIC) is considered a precursor of high-grade serous carcinoma, whereas the significance of the p53 signature remains unclear. In this study, we investigated the relationship between the p53 signature and the risk of ovarian cancer. Methods: We analyzed the clinicopathological findings and conducted DNA sequencing for variants of p53 signatures and STIC lesions isolated using laser capture microdissectionin 13 patients with pathogenic variants of who underwent RRSO and 17 control patients with the benign gynecologic disease. Results: pathogenic variants were detected significantly higher in RRSO group than control (p<0.001). No difference in the frequency of p53 signatures were observed between groups (53.8% vs 29.4%; p=0.17). sequencing and next-generation sequencing analysis in a patient with STIC and occult cancer revealed 2 mutations causing different p53 staining for STICs and another mutation shared between STIC and occult cancer. Conclusion: The sequence analysis for revealed 2 types of p53 signatures, one with a risk of progression to STIC and ovarian cancer with pathological variants in and the other with a low risk of progression without pathological variants in as seen in control.
( Taku Kobayashi ),( Katsuyoshi Matsuoka ),( Mamoru Watanabe ),( Tadakazu Hisamatsu ),( Fumihito Hirai ),( Joe Milata ),( Xingyuan Li ),( Nathan Morris ),( Vipin Arora ),( Tomoko Ishizuka ),( Koji Mat 대한장연구학회 2024 Intestinal Research Vol.22 No.2
Background/Aims: Mirikizumab is a p19-directed anti-interleukin-23 antibody with potential efficacy against ulcerative colitis (UC). We evaluated the efficacy and safety of mirikizumab in a Japanese subpopulation with moderately to severely active UC from the LUCENT-1 and LUCENT-2 studies. Methods: LUCENT-1 and LUCENT-2 were phase 3, randomized, double-blind, placebo-controlled trials of mirikizumab therapy in adults with moderately to severely active UC. LUCENT-1 was a 12-week induction trial where patients were randomized 3:1 to receive intravenous mirikizumab 300 mg or placebo every 4 weeks (Q4W). Patients achieving a clinical response with mirikizumab following the induction study were re-randomized 2:1 to double-blind treatment with either mirikizumab 200 mg or placebo subcutaneously Q4W during the 40-week maintenance study. The primary outcomes were clinical remission at week 12 of LUCENT-1 and week 40 of LUCENT-2. Results: A total of 137 patients enrolled in Japan were randomized to mirikizumab (n = 102) or placebo (n = 35). Compared with placebo, patients who received mirikizumab showed numerically higher clinical remission at week 12 of induction (32.4% [n = 33] vs. 2.9% [n = 1]) and at week 40 of maintenance (48.9% [n = 23] vs. 28.0% [n = 7]). A greater number of patients achieved key secondary endpoints in the mirikizumab group compared with placebo. The frequency of treatment-emergent adverse events was similar across mirikizumab and placebo groups. Efficacy and safety results observed in the Japanese subpopulation were generally consistent with those in the overall population. Conclusions: Mirikizumab induction and maintenance treatments were effective in Japanese patients with moderately to severely active UC. No new safety concerns were identified. (Intest Res 2024;22:172-185)
Shintaro Iwama,Tomoko Kobayashi,Hiroshi Arima 대한내분비학회 2021 Endocrinology and metabolism Vol.36 No.2
Immune-related adverse events (irAEs) affecting the endocrine glands are among the most frequent irAEs induced by immunecheckpoint inhibitors (ICIs) and include hypopituitarism, primary adrenal insufficiency, thyrotoxicosis, hypothyroidism, hypoparathyroidism, and type 1 diabetes mellitus. Since the incidence and clinical features of endocrine irAEs vary according to the ICI used,it is important to understand the characteristics of these irAEs and to manage each one appropriately. Since some endocrine irAEs,including adrenal crisis and diabetic ketoacidosis, are potentially life-threatening, predicting the risk of endocrine irAEs before theironset is critical. Several autoantibodies have been detected in patients who develop endocrine irAEs, among which anti-thyroid antibodies may be predictive biomarkers of thyroid dysfunction. In this review, we describe the clinical features of each endocrine irAEinduced by ICIs and discuss their potential biomarkers, including autoantibodies.
( Haruna Matsuda-hirose ),( Tomoko Yamate ),( Mizuki Goto ),( Akira Katoh ),( Hiroyuki Kouji ),( Yuya Yamamoto ),( Takashi Sakai ),( Naoto Uemura ),( Takashi Kobayashi ),( Yutaka Hatano ) 대한피부과학회 2019 Annals of Dermatology Vol.31 No.6
Background: The canonical Wnt/β-catenin signaling pathway is a fundamental regulatory system involved in various biological events. ICG-001 selectively blocks the interaction of β-catenin with its transcriptional co-activator cyclic AMP response element-binding protein (CBP). Recent studies have provided convincing evidence of the inhibitory effects of ICG-001 on Wnt-driven disease models, such as organ fibrosis, cancer, acute lymphoblastic leukemia, and asthma. However, the effects of ICG-001 in atopic dermatitis (AD) have not been investigated. Objective: To investigate whether β-catenin/CBP-dependent signaling was contributed in the pathogenesis of AD and ICG-001 could be a therapeutic agent for AD. Methods: We examined the effects of ICG-001 in an AD-like murine model generated by repeated topical application of the hapten, oxazolone (Ox). ICG-001 or vehicle alone was injected intraperitoneally every day during the development of AD-like dermatitis arising from once-daily Ox treatment. Results: Ox-induced AD-like dermatitis characterized by increases in transepidermal water loss, epidermal thickness, dermal thickness accompanied by increased myofibroblast and mast cell counts, and serum levels of thymic stromal lymphopoietin and thymus and activation- regulated chemokine, and decreases in stratum corneum hydration, were virtually normalized by the treatment with ICG-001. Elevated serum levels of periostin tended to be downregulated, without statistical significance. Conclusion: These results suggest that β-catenin/CBP-dependent signaling might be involved in the pathogenesis of AD and could be a therapeutic target. (Ann Dermatol 31(6) 631∼639, 2019)
Ochiai, Satoru,Nomoto, Yoshihito,Kobayashi, Shigeki,Yamashita, Yasufumi,Watanabe, Yui,Toyomasu, Yutaka,Kawamura, Tomoko,Takada, Akinori,II, Noriko,Sakuma, Hajime Asian Pacific Journal of Cancer Prevention 2016 Asian Pacific journal of cancer prevention Vol.17 No.4
Prostate cancer is the secondary most frequently diagnosed cancer in the world. Although numerous prospective randomized trial have been conducted to guide the management of patients with localized or locally advanced prostate cancer, few clinical trials targeting node-positive prostate cancer have been reported. Therefore, there are still controversies in the optimal management of node-positive prostate cancer. Recently, efficacy of multimodality treatment, including radiation therapy (RT), for such patients has been reported in several articles. The results indicate potential benefit of RT both in adjuvant therapy after prostatectomy and in definitive therapy for node-positive prostate cancer. The aim in this article was to summarize the current evidence for RT and evaluate the role in multimodality treatment for patients with node-positive prostate cancer.
Ochiai, Satoru,Nomoto, Yoshihito,Yamashita, Yasufumi,Watanabe, Yui,Toyomasu, Yutaka,Kawamura, Tomoko,Takada, Akinori,Ii, Noriko,Kobayashi, Shigeki,Sakuma, Hajime Asian Pacific Journal of Cancer Prevention 2016 Asian Pacific journal of cancer prevention Vol.17 No.2
Glioblastoma (GBM) is the most common and aggressive type of primary brain neoplasm. The current standard therapy for GBM consists of maximal surgical resection within safe limits, followed by radiation therapy (RT) and chemotherapy with temozolomide. Despite advances in treatment, the prognosis of GBM remains poor. Epileptic seizure is one of the most common symptoms in patients with GBM. Valproic acid (VPA), a histone deacetylase inhibitor, is often used as an anti-epileptic drug in patients with brain neoplasms due to its effectiveness and low toxicity profile. Several in vivo and in vitro studies have indicated that VPA has radiosensitizing effects for gliomas and radioprotective influence on normal brain tissue or hippocampal neurons. The results of several retrospective studies have also indicated potential benefit to improve survival of patients with GBM. Moreover, the promising treatment results of a phase 2 trial of concurrent radiation therapy, temozolomide, and VPA for patients with GBM have been recently reported. The use of VPA in patients with GBM has thus recently receiving more attention. In this article, we review the role of VPA in radiation therapy for GBM, focusing on the clinical evidence.
Yohei Nakayama,Shinichi Tabe,Kazuma Igarashi,Satoshi Moriya,Tsuyoshi Katsumata,Ryo Kobayashi,Shuta Nakagawa,Tomoko Nishino,Namiko Fukuoka,Kota Hosono,Mai Yamasaki,Yosuke Yamazaki,Moe Ogihara-Takeda,Sh 대한치주과학회 2024 Journal of Periodontal & Implant Science Vol.54 No.4
Purpose: Enamel matrix derivative (EMD) has demonstrated beneficial effects on wound healing following surgery. However, the effects of recombinant human fibroblast growth factor 2 (rhFGF-2) in periodontal regeneration therapy have not been extensively studied. This retrospective study was conducted to compare the wound healing outcomes of the modified papilla preservation technique (mPPT) between EMD and rhFGF-2 therapies. Methods: A total of 79 sites were evaluated for early wound healing using the modified early wound healing index (mEHI), which included 6 items: incision, fibrin clotting, step, redness, swelling, and dehiscence. A numeric analog scale, along with postoperative images of the 6 mEHI items, was established and used for the evaluations. The inter-rater reliability of the mEHI was assessed via intraclass correlation coefficients (ICCs). After adjusting for factors influencing the mPPT, the differences in mEHI scores between the EMD and rhFGF-2 groups were statistically analyzed. Additionally, radiographic bone fill (RBF) was evaluated 6 months after surgery. Results: The ICC of the mEHI was 0.575. The mEHI, redness score, and dehiscence scores were significantly higher in the rhFGF-2 group (n=33) than in the EMD group (n=46). Similar results were observed in the subgroup of patients aged 50 years or older, but not in those younger than 50 years. In the subgroup with non-contained bone defects, related results were noted, but not in the subgroup with contained bone defects. However, early wound healing did not correlate with RBF at 6 months after surgery. Conclusions: Within the limitations of this study, the findings suggest that early wound healing following the use of mPPT with rhFGF-2 is somewhat superior to that observed after mPPT with EMD. However, mEHI should be improved for use as a predictive tool for early wound healing and to reflect clinical outcomes after surgery.